Clinical trial
Herceptin and GM-CSF for Metastatic Breast Cancer
NCT00429104 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00429104 |
|---|---|
| Title | Herceptin and GM-CSF for Metastatic Breast Cancer |
| Official title | Phase II Study of GM-CSF to Overcome Herceptin-Resistant HER-2/Neu-Overexpressing Metastatic Breast Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Herceptin, GM-CSF |
| Enrollment | 18 |
| Start date | Aug 1, 2002 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jan 31, 2007 |
| Last update posted | Dec 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: